AROLDI, ANDREA

AROLDI, ANDREA  

DIPARTIMENTO DI MEDICINA E CHIRURGIA (SCHOOL OF MEDICINE AND SURGERY)  

Mostra records
Risultati 1 - 20 di 27 (tempo di esecuzione: 0.011 secondi).
Titolo Tipologia Data di pubblicazione Autori File
Anaplastic Lymphoma Kinase (ALK) Inhibitors Enhance Phagocytosis Induced by CD47 Blockade in Sensitive and Resistant ALK-Driven Malignancies 01 - Articolo su rivista 2024 Malighetti, FedericaVilla, MatteoMauri, MarioPiane, SimoneCrippa, ValentinaCrespiatico, IlariaCocito, FedericaBossi, ElisaSteidl, CarolinaCivettini, IvanScollo, ChiaraRamazzotti, DanieleGambacorti-Passerini, CarloPiazza, RoccoMologni, LucaAroldi, Andrea
Evaluating the performance of large language models in haematopoietic stem cell transplantation decision-making 01 - Articolo su rivista 2024 Civettini, IvanZappaterra, AriannaGranelli, Bianca MariaRindone, GiovanniAroldi, AndreaBonfanti, StefanoColombo, FedericaFedele, MarilenaPerfetti, PaolaTerruzzi, ElisabettaGambacorti-Passerini, CarloRamazzotti, DanieleCavalca, Fabrizio +
First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosis 01 - Articolo su rivista 2024 Crespiatico I.Mastini C.D'Aliberti D.Mauri M.Mercado C. M.Fontana D.Spinelli S.Crippa V.Inzoli E.Manghisi B.Civettini I.Ramazzotti D.Sangiorgio V.Brambilla V.Aroldi A.Barone C.Orsenigo R.Serafini M.Mottadelli F.Cazzaniga G.Pagni F.Azzoni E.Gambacorti Passerini C.Elli E. M.Mologni L.Piazza R. +
Hb Monza: A novel extensive HBB duplication with preserved α-β subunit interaction and unstable hemoglobin phenotype 01 - Articolo su rivista 2024 Civettini, IvanZappaterra, AriannaCorti, PaolaAroldi, AndreaBiondi, AndreaCavalca, FabrizioCrippa, ValentinaCrosti, FrancescaFerrari, Giulia MariaMalighetti, FedericaMologni, LucaPiperno, AlbertoRamazzotti, DanieleScollo, ChiaraGambacorti-Passerini, Carlo +
Idiopathic erythrocytosis: a germline disease? 01 - Articolo su rivista 2024 Elli, E. M.Mauri, M.D’Aliberti, D.Crespiatico, I.Fontana, D.Redaelli, S.Pelucchi, S.Spinelli, S.Manghisi, B.Cavalca, F.Aroldi, A.Ripamonti, A.Palamini, S.Mottadelli, F.Massimino, L.Ramazzotti, D.Cazzaniga, G.Piperno, A.Gambacorti-Passerini, C.Piazza, R. +
A monocentric analysis of the long-term safety and efficacy of crizotinib in relapsed/refractory ALK+ lymphomas 01 - Articolo su rivista 2023 Rindone, GiovanniAroldi, AndreaBossi, ElisaVerga, LuisaZambrotta, GiovanniTarantino, SaraPiazza, RoccoGambacorti-Passerini, Carlo +
ALK inhibitors increase ALK expression and sensitize neuroblastoma cells to ALK.CAR-T cells 01 - Articolo su rivista 2023 Aroldi A. +
Characterization of SARS-CoV-2 Mutational Signatures from 1.5+ Million Raw Sequencing Samples 01 - Articolo su rivista 2023 Aroldi, AndreaAngaroni, FabrizioD’Aliberti, DeborahSpinelli, SilviaCrespiatico, IlariaCrippa, ValentinaPiazza, RoccoGraudenzi, AlexRamazzotti, Daniele
Effects of blocking CD24 and CD47 'don't eat me' signals in combination with rituximab in mantle-cell lymphoma and chronic lymphocytic leukaemia 01 - Articolo su rivista 2023 Aroldi, AMauri, MRamazzotti, DVilla, MMalighetti, FCrippa, VCocito, FBorella, CBossi, ESteidl, CScollo, CMologni, LPiazza, RGambacorti Passerini, C +
Evolutionary signatures of human cancers revealed via genomic analysis of over 35,000 patients 01 - Articolo su rivista 2023 Fontana, DCrespiatico, ICrippa, VMalighetti, FVilla, MAngaroni, FAroldi, AAntoniotti, MCaravagna, GPiazza, RGraudenzi, AMologni, LRamazzotti, D +
Advances and Hurdles in CAR T Cell Immune Therapy for Solid Tumors 01 - Articolo su rivista 2022 Aroldi A. +
Caution in using second generation tyrosine kinase inhibitor, especially for first line therapy of chronic myeloid leukemia 01 - Articolo su rivista 2022 Gambacorti-Passerini, CarloAroldi, AndreaFontana, DilettaPiazza, RoccoAntolini, Laura +
Humoral and cellular immune response in patients with hematological disorders after two doses of BNT162b2 mRNA COVID-19 vaccine: A single-center prospective observational study (NCT05074706) 01 - Articolo su rivista 2022 Bossi, ElisaAroldi, AndreaBorin, Lorenza MariaVerga, LuisaFontana, DilettaCocito, FedericaManghisi, BeatriceRindone, GiovanniCavalca, FabrizioRipamonti, AlessiaAntolini, LauraPiazza, Rocco GiovanniGambacorti-Passerini, Carlo +
Post-Transplant Lymphoproliferative Disease (PTLD) after Allogeneic Hematopoietic Stem Cell Transplantation: Biology and Treatment Options 01 - Articolo su rivista 2022 Aroldi A. +
Tyrosine Kinase Inhibitor discontinuation in Chronic Myeloid Leukemia: eligibility criteria and predictors of success 01 - Articolo su rivista 2022 Inzoli E.Aroldi A.Piazza R.Gambacorti Passerini C.
Validation of a new NGS-based myeloid panel in acute myeloid leukemia: A single-center experience 01 - Articolo su rivista 2022 Steidl, CarolinaAroldi, AndreaMologni, LucaCrespiatico, IlariaFontana, DilettaMastini, CristinaBorin, LorenzaPiazza, RoccoGambacorti-Passerini, Carlo +
Clinical Benefit of Lenzilumab in Cases of Coronavirus Disease 2019 01 - Articolo su rivista 2021 Aroldi, AGambacorti Passerini, C +
Transfusion of blood products derived from SARS-CoV-2+ donors to patients with hematological malignancies 01 - Articolo su rivista 2021 Gambacorti Passerini C.Aroldi A.Piazza R. +
Integrated Genomic, Functional, and Prognostic Characterization of Atypical Chronic Myeloid Leukemia 01 - Articolo su rivista 2020 Fontana, DilettaRamazzotti, DanieleAroldi, AndreaRedaelli, SaraMagistroni, VeraPirola, AlessandraMassimino, LucaMastini, CristinaBrambilla, VirginiaBombelli, SilviaElli, Elena MariaFumagalli, MonicaPerego, Roberto APagni, FabioMologni, LucaPiazza, RoccoGambacorti-Passerini, Carlo +
Phase two study of crizotinib in patients with anaplastic lymphoma kinase (ALK) positive anaplastic large cell lymphoma relapsed/refractory to chemotherapy 01 - Articolo su rivista 2020 Bossi E.Aroldi A.Steidl C.Verga L.Fontana D.Sharma G. G.Mologni L.Piazza R.Gambacorti Passerini C. +